Anti-albuminuric effects of spironolactone and its effect along with ramipril in type-2 diabetic nephropathy

Simple item page
dc.contributor.authorGiri, Richaen_US
dc.contributor.authorNaresh, Ashishen_US
dc.contributor.authorKushwaha, J. S.en_US
dc.contributor.authorKumar, Brijeshen_US
dc.contributor.authorVerma, R. K.en_US
dc.contributor.authorKhan, Mohd. Imranen_US
dc.date.accessioned2020-04-09T07:41:22Z
dc.date.available2020-04-09T07:41:22Z
dc.date.issued2019-01
dc.description.abstractBackground: The study was conducted to evaluate and compare the protective effects of spironolactone (alone) and its effects along with ACE inhibitor (ramipril) on diabetics (30-70year) in relation to proteinuria and state of diabetic nephropathy.Methods: A comparative, prospective, non-randomized, non-blinded experimental study was conducted on 56 patients (30-70year) of diagnosed type 2 diabetes mellitus showing proteinuria. Total duration of study was about one year from October 2017 to October 2018. Patients were divided in two groups, group A (n=28, spironolactone 25mg and ramipril 5mg) and group B (n=27, spironolactone 25mg). Subjects were followed over 12weeks and baseline and 12-week urine ACR being compared.Results: Both the group after receiving respective drug were followed for 3month duration and response were assessed by measuring urine ACR value at end of 3months. Mean values of baseline and follow up urine ACR for group A and group B were 471.5±465.62, 244.66±237.54 and 474.88±438.94, 268.42±268.16 respectively, P value found to be >0.05 at 95%C.I. It was observed that percentage reduction of urine ACR were 48% and 43.47% in group A and group B respectively.Conclusions: In the study, it was concluded that spironolactone had significant effect over proteinuria reduction over follow up period in patient with diabetic nephropathy though there was no additional statistically significant advantage of addition of spironolactone and ACE inhibitor over proteinuria reduction. Significant reduction of proteinuria occurred in both group A and group B over 12weeks follow up period, 48 % reduction in group A and 43.47% in group B. This difference proved statistically not significant after applying independent t-test.en_US
dc.identifier.affiliationsDepartment of Medicine, GSVM Medical College, Kanpur, Uttar Pradesh, Indiaen_US
dc.identifier.citationGiri Richa, Naresh Ashish, Kushwaha J. S., Kumar Brijesh, Verma R. K., Khan Mohd. Imran. Anti-albuminuric effects of spironolactone and its effect along with ramipril in type-2 diabetic nephropathy. International Journal of Advances in Medicine. 2019 Jan; 6(1): 140-145en_US
dc.identifier.issn2349-3925
dc.identifier.issn2349-3933
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/194183
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber1en_US
dc.relation.volume6en_US
dc.source.urihttps://dx.doi.org/10.18203/2349-3933.ijam20190120en_US
dc.subjectACE-Angiotensin converting enzymeen_US
dc.subjectACR-Albumin creatinine ratioen_US
dc.titleAnti-albuminuric effects of spironolactone and its effect along with ramipril in type-2 diabetic nephropathyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijam2019v6n1p140.pdf
Size:
200.34 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Advances in Medicine